Telix at SNMMI 2026

Telix is in Los Angeles this week for the SNMMI 2026 Annual Meeting.

This year’s program features seven abstracts from across Telix’s oncology portfolio, including three oral presentations exploring novel imaging approaches in clear cell renal cell carcinoma, thyroid cancer and bone marrow dosimetry.

Poster presentations will also cover prostate cancer imaging (BiPASS™), kidney cancer therapy (LUTEON), recurrent glioblastoma therapy (IPAX BrIGHT), and discovery-stage radiopharmaceutical science.

Meet us at Booth #745 to connect with Telix and learn more about our theranostic pipeline, commercial portfolio and manufacturing capabilities.

TLX250-Px, TLX250-Tx, TLX400-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction.

Learn more about the presentations below

Los Angeles, CA

May 30 – June 2 2026

Abstract presentations 

Oral Presentations
Poster Presentations
Oral Presentations
Jonathan Kim


Massachusetts General Hospital
The role of 89Zr-girentuximab PET/CT (TLX250-Px) in detection and management of primary and metastatic clear cell renal cell carcinoma; a single-center experience

SS11 Genitourinary Diagnosis and Imaging
SS Room 3 | May 31 | 12:40 PM – 12:50 PM PDT

Joan Urena Poch


Rostock
Value of FAP PET/CT (TLX400-Px) in the preoperative assessment of a localized recurrence of differentiated thyroid cancer

SS24 Oncology Clinical Diagnosis and Therapy
Scientific Session: Endocrine and Head and Neck

SS Room 4 |June 1 | 1:45 PM – 1:55 PM PDT

Quyen Tran


UC Davis
A Mathematical Model for Image-Derived Blood-Input Functions in Quantitative Dynamic PET

IS09 Advanced Methodology of Data
Analysis and Dosimetry
IS Room | Jun 2 | 11:30 AM – 11:40 AM PDT

Poster Presentations
Wayne Brisbane


UCLA Health
Phase 3 study to assess safety and efficacy of TLX250-Tx ([177Lu]-girentuximab) in advanced relapsed or recurrent ccRCC (LUTEON) NCT07197580

MTA03 Oncology Clinical Diagnosis and
Therapy Scientific Session
Screen 53 | May 31 | 5:30 PM – 6:15 PM PDT

Neeta Pandit-Taskar


University of Pittsburgh
Phase 3 study to assess safety and efficacy of 177Lu-girentuximab (TLX250-Tx) in advanced relapsed or recurrent ccRCC (LUTEON) NCT07197580

MTA06 Oncology Clinical Diagnosis and
Therapy Scientific Session
Screen 44 | June 1 | 10:30 AM – 11:15 AM PDT

Jonathan Kim


Massachusetts General Hospital
89Zr-girentuximab (TLX250-Px) PET/CT for detecting residual post-ablative clear cell renal cell carcinoma

MTA06 Oncology Clinical Diagnosis and
Therapy Scientific Session
Screen 18 | June 1 | 10:30 AM – 11:15 AM PDT

Stephen A. Graves


University of Iowa
FNIH PDIB bone marrow dosimetry: seven image-based workflows for SPECT/CT-only implementation

MTA07 Educational Exhibits Meet
the Author Session
Science Pavilion | Jun 1 | 1:15 PM – 2:00 PM PDT

Andrew Scott


Austin Health
Pivotal study of 131I-iodofalan (TLX101-Tx) with or without lomustine vs lomustine alone for the treatment of patients with radiographically confirmed recurrent GBM at first recurrence (IPAX BrIGHT) NCT07100730

MTA08 Neurosciences
Screen 42 | June 1 | 2:45 PM – 3:30 PM PDT

Macy Perez


Telix IsoTherapeutics
Development and optimization of DFOsq chelation to minibodies

MTA11 Oncology: Discovery &
Translational Meet the Author Session
Screen 43 | June 2 | 11:30 AM – 12:15 PM PDT